Over the last few years, the pharmaceutical industry’s capital investment strategy has been undeniably focused on biologics. Spurred by the global demand for COVID-19 vaccines and the acceleration of cell and gene therapies, biologics have attracted the lion’s share of funding, infrastructure and talent development since 2020.
From cutting-edge monoclonal antibody treatments to viral vector production for advanced therapies, biologics have been the focus of nearly every major pharma player. It’s no surprise that young engineers and scientists entering the industry between 2020 and 2024 have been keen to build their careers in this high-growth area. As the sector rapidly scaled up, roles in sterile fill-finish, upstream and downstream processing, and injectables manufacturing became the new norm.
Europe leading the charge
However, a subtle but significant shift is beginning to reshape the pharmaceutical landscape—and it’s one that may soon bring new challenges for the entire industry.
The weight loss drugs revolution
This is more than a formulation change; it’s a potential pivot in global manufacturing strategy. Tablets and capsules require entirely different equipment, facility layouts, process validation strategies, and skill sets. For companies who have spent the last five years building biologics-heavy infrastructure, the shift toward oral solid dose (OSD) manufacturing may present a serious talent bottleneck.
A skill set shortage looms
This is particularly critical in Europe, where the volume of biologics-based hiring in recent years may have inadvertently thinned the talent pool for traditional OSD roles. From process engineers to validation experts, the demand for professionals with a solid background in oral dosage forms is expected to increase sharply, especially if clinical trials for these weight loss tablets continue to succeed.
What this means for candidates
For those with existing OSD experience, your skill set may soon be in higher demand than ever. The upcoming transition will require experienced professionals who can hit the ground running, guide facility adaptations, and train new team members.
Looking ahead: Strategic workforce planning is essential
Kam Khalighi, Operations Manager at Blackfield Associates, commented, “As a specialist recruitment partner in the life sciences industry, we’re keeping a close eye on these evolving trends. Whether you’re a hiring manager preparing for pipeline expansion or a candidate looking to future-proof your career, now is the time to act.”
Let’s start a conversation – because the future of pharma won’t wait. Contact us today using the button below and Kam or another of his specialist team will be in touch.
